Adam's Take

Adam's Take

Biotech’s ‘distracted boyfriend’ is $3 billion richer. His fellow investors are still waiting for their share

By Adam Feuerstein

Adam's Take

Mark Schoenebaum was the best biotech analyst ever. Better still, he was a great person

By Adam Feuerstein

Adam's Take

FDA’s Sarepta rejection is rooted in the past, and will weigh on its future

By Adam Feuerstein

Adam's Take

This troubled biotech needed cash, so it turned to a predatory lender: its own CEO

By Adam Feuerstein

Adam's Take

Sarepta’s bad week raised questions about its gene therapy program. Here are some answers

By Adam Feuerstein

Adam's Take

Show us the data: Bluebird raises questions by sitting on results of CAR-T drug critical to its future

By Adam Feuerstein

Adam's Take

With another trial failure, it may be time to revoke the approval of Acadia Pharma’s anti-psychosis drug

By Adam Feuerstein

Adam's Take

The FDA erred in approving new women’s libido drug; don’t reward Palatin Technologies

By Adam Feuerstein

Adam's Take

Fibrogen’s obtuse disclosures about anemia pill raise concerns over heart safety, putting approval at risk

By Adam Feuerstein

Adam's Take

Sales of Amarin’s heart drug are surging, but the stock not so much. Here’s why

By Adam Feuerstein

Adam's Take

Taking the measure of small-cap biotech: ResTORbio, Trovagene, Atossa Genetics

By Adam Feuerstein

Biotech

Biogen-Eisai partnership may be hitting a rough patch following Alzheimer’s drug blowup

By Adam Feuerstein

Adam's Take

Cowen polled investors and doctors on the outlook for new biotech drugs. Here’s what they said

By Adam Feuerstein

Adam's Take

Taking the measure of small-cap biotech: Bio-Path Holdings, CytoDyn

By Adam Feuerstein

Adam's Take

Suddenly, the Bristol-Celgene deal is looking shaky. What might be next for Celgene?

By Adam Feuerstein

Adam's Take

Wait … what? MannKind posts best-ever quarter of inhaled insulin product sales

By Adam Feuerstein

Adam's Take

Karyopharm hides higher death rate tied to blood cancer drug, dimming approval hopes

By Adam Feuerstein

Adam's Take

Taking the measure of small-cap biotech: Fennec Pharma, Actinium Pharma

By Adam Feuerstein

Adam's Take

What’s next in NASH? 6 things to know following the failure of Gilead’s lead drug for fatty liver disease

By Adam Feuerstein

Adam's Take

Taking the measure of small-cap biotech: Bellus Health, OncoSec Medical

By Adam Feuerstein

Adam's Take

Gilead’s new CEO hasn’t shown up for work yet, leaving the biotech rudderless, investors anxious

By Adam Feuerstein

Adam's Take

Taking the measure of small-cap biotech: Rexahn, Omeros, and Cel-Sci

By Adam Feuerstein

Biotech

Aurinia’s flop in dry-eye trial brings an unexpected victory — and a shot at challenging Allergan

By Adam Feuerstein

Adam's Take

Lipocine fatty liver drug study results don’t hold up to scrutiny

By Adam Feuerstein

Adam's Take

Amarin’s CEO drops enough JPM19 hints to know Vascepa sales driving higher

By Adam Feuerstein

Adam’s Take

Cel-Sci is publicly upbeat about its cancer drug. Privately it’s trying to sell stock

Investors are deeply skeptical of Biogen’s Alzheimer’s claims. They still think it could win approval

A cancer company has misled investors repeatedly about its drug. It’s time for some truth-telling

The bearish view of Acadia Pharma’s antipsychotic drug takes a hit with positive trial results

Biotech’s ‘distracted boyfriend’ is $3 billion richer. His fellow investors are still waiting for their share

Mark Schoenebaum was the best biotech analyst ever. Better still, he was a great person

FDA’s Sarepta rejection is rooted in the past, and will weigh on its future

This troubled biotech needed cash, so it turned to a predatory lender: its own CEO

Sarepta’s bad week raised questions about its gene therapy program. Here are some answers

Show us the data: Bluebird raises questions by sitting on results of CAR-T drug critical to its future

With another trial failure, it may be time to revoke the approval of Acadia Pharma’s anti-psychosis drug

The FDA erred in approving new women’s libido drug; don’t reward Palatin Technologies

Fibrogen’s obtuse disclosures about anemia pill raise concerns over heart safety, putting approval at risk

Sales of Amarin’s heart drug are surging, but the stock not so much. Here’s why

Taking the measure of small-cap biotech: ResTORbio, Trovagene, Atossa Genetics

Biogen-Eisai partnership may be hitting a rough patch following Alzheimer’s drug blowup

Cowen polled investors and doctors on the outlook for new biotech drugs. Here’s what they said

Taking the measure of small-cap biotech: Bio-Path Holdings, CytoDyn

Suddenly, the Bristol-Celgene deal is looking shaky. What might be next for Celgene?

Wait … what? MannKind posts best-ever quarter of inhaled insulin product sales

Karyopharm hides higher death rate tied to blood cancer drug, dimming approval hopes

Taking the measure of small-cap biotech: Fennec Pharma, Actinium Pharma

What’s next in NASH? 6 things to know following the failure of Gilead’s lead drug for fatty liver disease

Taking the measure of small-cap biotech: Bellus Health, OncoSec Medical

Gilead’s new CEO hasn’t shown up for work yet, leaving the biotech rudderless, investors anxious

Taking the measure of small-cap biotech: Rexahn, Omeros, and Cel-Sci

Aurinia’s flop in dry-eye trial brings an unexpected victory — and a shot at challenging Allergan

Lipocine fatty liver drug study results don’t hold up to scrutiny

Amarin’s CEO drops enough JPM19 hints to know Vascepa sales driving higher